May 14, 2019 / 04:20PM GMT
Tazeen Ahmad - BofA Merrill Lynch, Research Division - VP
The senior biotech analyst here at Bank of America Merrill Lynch. It's our pleasure to introduce Ascendis this morning. Speaking for Ascendis, sitting next to me, is Jan Mikkelsen, Chief Executive Officer; and sitting next to him is Scott Smith, Chief Financial Officer and Chief Strategist of the company.
This will be a Q&A session. Feel free to ask any questions that you might have. And maybe we can kick it off, Jan, with the recent data that you presented for growth hormone deficiency. So if you can give us a 2-minute summary of Ascendis and what's happening and maybe start off by focusing on GHD and then we can go from there.
Jan Møller Mikkelsen - Ascendis Pharma A/S-President - CEO, Member of Executive Board & Executive Director
First, thanks a lot, Tazeen. It's a pleasure to be here. And also this is one of the first opportunities we have really to go out to a conference after our Phase III heiGHt data. So it's fair --
Ascendis Pharma A/S at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers